Acelyrin Q1 2023 Earnings Report $2.50 -0.11 (-4.04%) As of 10:57 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Earnings HistoryForecast Acelyrin EPS ResultsActual EPS-$2.11Consensus EPS -$0.88Beat/MissMissed by -$1.23One Year Ago EPSN/AAcelyrin Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAcelyrin Announcement DetailsQuarterQ1 2023Date6/15/2023TimeN/AConference Call ResourcesPress ReleaseSLRN Earnings HistoryPowered by Remove Ads Acelyrin Earnings HeadlinesSTOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating The Merger - SLRN, TURN, BHLB, MHLDMarch 30 at 9:30 PM | morningstar.comAcelyrin, Inc. (SLRN): One of the Best Short-Term Stocks to Buy Right NowMarch 18, 2025 | msn.com7 Stocks Set to Win Big Under Trump’s America First Agenda 🚀The Trump economy is back in full force, and it’s creating huge opportunities for investors. With Trump pushing for lower taxes, fewer regulations, tariffs on foreign competitors, and domestic manufacturing dominance, some stocks are set to skyrocket in value—while others will be left behind. That’s why we put together this free report revealing the 7 MAGA stocks poised to thrive in 2025.March 31, 2025 | TradingTips (Ad)ACELYRIN Adopts Limited-Duration Stockholder Rights PlanMarch 13, 2025 | globenewswire.comAcelyrin: Potential Buyout Led By Concentra BiosciencesMarch 12, 2025 | seekingalpha.comIs Acelyrin, Inc. (SLRN) the Best Micro Cap Stock to Buy Now?March 7, 2025 | insidermonkey.comSee More Acelyrin Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Acelyrin? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Acelyrin and other key companies, straight to your email. Email Address About AcelyrinAcelyrin (NASDAQ:SLRN), a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.View Acelyrin ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Intuitive Machines Gains After Earnings Beat, NASA Missions AheadCintas Delivers Earnings Beat, Signals More Growth AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside?These 3 Q1 Earnings Winners Will Go HigherWhat Is the Price-to-Earnings (P/E) Ratio? Upcoming Earnings Bank of New York Mellon (4/11/2025)BlackRock (4/11/2025)JPMorgan Chase & Co. (4/11/2025)Progressive (4/11/2025)Wells Fargo & Company (4/11/2025)Interactive Brokers Group (4/15/2025)Bank of America (4/15/2025)Citigroup (4/15/2025)Johnson & Johnson (4/15/2025)Morgan Stanley (4/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
